http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2297794-C1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3c85619cb889da1054b1c2838c0a5785
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B8-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-14
filingDate 2005-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2007-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4385967475de538aa3dd2fe03b0c1ab1
publicationDate 2007-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber RU-2297794-C1
titleOfInvention Method for selecting pregnant women during i-ii trimesters for carrying out the correcting therapy of thyroid dysfunction
abstract FIELD: medicine, obstetrics. n SUBSTANCE: beforehand it is necessary to detect the level of free thyroxine and thyrotropic hormone in blood serum to conduct ultrasound thyroid testing. Moreover, if the level of free thyroxine corresponds to or is below 12.1 pM/l, - 15 th percentile of available normative values, and the level of thyrotropic hormone corresponds to about 2-4 mIU/l, in case of increased thyroid volume by 30%, not more against the norm and/or diffuse structural thyroid alterations it is important to prescribe preventive therapy for pregnant women with levothyroxine preparations at the dosage of 25-75 mcg/d. The innovation enables to prevent the complications of pregnancy and improve perinatal result. n EFFECT: higher efficiency. n 3 ex
priorityDate 2005-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419565407
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID25201348

Total number of triples: 16.